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Varicose Veins
•Varicose veins are tortuous 
and dilated veins caused by 
incompetent valves in the 
long saphenous vein /short
saphenous vein or perforater 
systems
• 30 million Americans and 
40 million Europeans suffer 
from venous reflux disease
•May cause complications of 
• Ezcema
• Pigmentation
• ulceration
VenaSeal™ Cyanoacrylate for 
Varicose Veins Treatment
•This product had European 
Conformite Europeen (CE) 
Mark approval in September 
2011, and United States FDA 
approved February 2015.
•The VenaSeal™ closure 
system is commercially 
available in Europe, Australia, 
Hong Kong, New Zealand, 
UAE, and Canada. 
 Proprietary, advanced formulation, 
high grade medical adhesive
– Designed specifically for saphenous vein disease 
treatment
– Seals vein along treatment length without surgery or 
burning
– Has European CE Mark approval in September 2011
• VenaSeal has been used to treat over 1,700 veins in 
patients in Europe
– FDA approved February 2015
 Proprietary catheter design
– Engineered to be inert to adhesive 
– Provides exceptional high visibility under ultrasound 
guidance
 Proprietary dispenser gun
– Calibrated to deliver precise amount of Sapheon vein 
sealant adhesive
Aim of Study
• To evaluate the safety 
and efficacy of 
endovenous injection of 
cyanoacylate in treating
symptomatic varicose 
veins 
The procedure takes place in the operating theatre: local anaesthesia 
and monitored anaesthetic care with intraoperative ultrasound
After successful cannulation of the LSV, a guidewire is passed under ultrasound 
guidance. In the meantime, the cyanoacylate is being drawn up and prepared.
The tip of the catheter is 4cm from the saphenofemoral junction. 
Two injections of approximately 
0.09 milliliters were given 1 cm apart at 
this location, followed by a 3-minutes
period of local compression, and then 
repeated injections and 30-second 
ultrasound probe and hand compression 
sequences until the entire length of the 
target vein segment was treated. 
Methods & Materials
• Patients with primary varicose veins due to 
duplex-proven incompetent long saphenous veins 
(LSV) were recruited
• All the patients had pre-operative duplex to 
confirm saphenofemoral junction and long 
saphenous vein incompetence
• All the procedures took place as day-case in our 
Minimally Invasive Surgical Centre under local 
anaesthesia/ monitored anaesthetic care, without 
tumescence anaesthesia
Outcome Measures
Primary Outcome Measures 
• Procedure success rate- saphenous vein obliteration rate
• Cumulative probability of recurrent varicose veins within 
24 months after treatment, with serial clinical and duplex 
examination of patient at 1 week, 3 months, 6 months, 1 
year, 2 years. 
Secondary Outcome Measures: 
• Quality of life (as measured by SSF36) - Questionnaire 
style clinical score/ venous clinical severity score 
(assessment of pain, edema, venous claudication, 
pigmentation, lipodermatosclerosis, ulcer size), at pre-op, 1 
week post op, 3 months post op, 6 months post-op, 1, 2, 
years post op.
• Ecchymosis score
• Side-effects or major events from this treatment modality
Results
• Thirty-three incompetent LSVs (mean 
diameter 0.9 (range 0.6-1.1)cm) in 17 
patients (4 males, median age 62.6 
(range 39-78) from September 2014 to 
January 2015 were included.
• CEAP: C3-20, C4a-10, C4b-1, C5-
1,C6-1. 
The Result
•Minimally invasive with very small 
wounds and minimal bruising
•Technical success in all cases
•Avulsions of varicosities under local 
anesthesia took place in same setting
Completion duplex: successful 
obliteration of long saphenous vein
Completion duplex: absence of 
thrombus or clots in deep femoral vein
Results
• All the patients were ambulatory 
immediately post-operatively and 
discharged on the same day. 
• Median follow-up period was 1.28 (range 
0.26-3.52) months, and no deep vein 
thrombosis was detected 
• All the treated LSV were successfully 
obliterated, with the mean LSV stump of 
2.68 (range 0.8-6.5cm) cm. Mean post-
operative pain score was 0.82 (range 0-3; 
normal 0-10). 
Follow up duplex showed no DVT, and successful obliteration of LSV
Questionnaire Results
• Mean scores preoperatively and 1 month 
postoperative for: venous severity score, 
Aberdeen varicose vein questionnaire, SF36
(physical health), SF36 (mental health) were: 7.3 
to 2.2 (student’s t test: p<0.001), 24.9 to 5.0 
(p<0.001). 44.8 to 44.0 (p=0.751), 58.9 to 56.1 
(p=0.094) respectively 
• There were no side-effects or major events, but 
one patient developed minor wound infection 
treated with antibiotics
• No clinical recurrences of varicosities
Summary
• Our short-term 
experience showed that 
endovenous 
cyanoacrylate injection 
for LSV incompetence 
was safe and effective
• Longer term results are 
anticipated

